Melanoma patient’s metastases disappear after NeoOncovac treatment, scientist says

The distinction matters twice over. Disappearance of detected cancer is encouraging for the patient. It does not, by itself, establish that the improvement will last—or how much the vaccine contributed to it.

Alexander Gintsburg, scientific director of the Gamaleya Research Center, disclosed the preliminary outcome in remarks carried by Russian media and reported by the Saudi newspaper Okaz on November 13. These are accounts of his observations, not independently verified patient records or findings from a published controlled trial. GxP News also reported his account; that is another report of the same finding, not independent clinical confirmation.⁠1⁠13

The man began receiving the treatment in April 2026, according to Okaz. Russia’s National Medical Research Radiological Centre announced its first clinical experience with the vaccine on April 1, identifying its P. Hertsen branch in Moscow as the treatment site. Vesti subsequently reported Gintsburg’s statement that the first patient’s course required ten injections.⁠1⁠23⁠15

Metastases are cancer that has spread beyond its original site. Their reported disappearance is therefore a meaningful observation, not simply an indication that the patient completed his injections. What is missing is the clinical detail needed to interpret the result precisely: scan measurements, the patient’s exact stage, the extent of disease when vaccination began and the formal criteria used to assess his response. The public outcome account does not provide those answers.⁠1⁠13⁠23

NeoOncovac is intended for people who already have cancer. It is a therapeutic mRNA vaccine, designed around the genetic characteristics of an individual patient’s tumor, with the aim of helping the immune system recognize and attack cancer cells. It is not a routine vaccination to prevent melanoma, and this report is not evidence that a single vaccine can treat every kind of cancer.⁠1⁠20

The personalized design is the treatment’s rationale, not proof of its effectiveness. A vaccine can be built to direct an immune response toward a tumor and still require clinical testing to show whether that response produces a worthwhile, lasting benefit.

The radiological centre says it and Gamaleya received permission for clinical use in late 2025. That establishes the institutions’ account of authorization to administer the treatment. The available documentation does not establish an unrestricted marketing authorization or supply the underlying authorization number, complete conditions and prescribing information. Permission to use a treatment and evidence demonstrating how well it works are separate questions.⁠21⁠22

The central unanswered question is not whether the reported improvement would be welcome. It is what produced it. A sufficiently complete record of the patient’s cancer treatment before and during vaccination is needed to assess NeoOncovac’s contribution. The available outcome reports do not allow that contribution to be separated from other cancer care, and they do not justify treating the vaccine as the sole explanation.⁠13⁠23

Nor do the supplied institutional announcements and reporting establish a comparator group, a trial protocol, a registry identifier or a peer-reviewed NeoOncovac efficacy dataset. That does not prove such materials do not exist. It means this account cannot support a calculation of the vaccine’s effectiveness, a comparison with existing treatment or a reliable assessment of its long-term risks. Unreported adverse effects cannot be counted as evidence of safety.⁠21⁠23⁠13

The recipient count also needs careful reading. Gintsburg says six patients have received NeoOncovac; he has not reported that all six completed treatment or experienced the first patient’s outcome. The second patient was described as midway through a ten-dose course. Without outcomes across the recipients, six is a treatment count, not a response rate.⁠1

The plan is to treat 20 patients in total by the end of 2026 at the Herzen institute in Moscow. That is a target—not 20 completed treatments, and not 20 additional patients on top of the six already reported. Expanding treatment could provide more useful evidence, but only if outcomes, accompanying therapies and harms are documented rather than reduced to a succession of favorable anecdotes.⁠1⁠12

For the first patient, follow-up means monthly high-resolution CT examinations, checking lymph nodes and organs elsewhere in the body. The stated monitoring plan runs for three years. Gintsburg separately described five years as the period needed to assess full recovery. The account does not explain how the three-year plan connects to that longer benchmark.⁠1

Those horizons should not be collapsed into a promise. Four months is an early observation window, not proof of permanent recovery. Nor should the disappearance of previously detected metastases be relabeled a formally established complete remission on the information supplied. Even the favorable result being reported is narrower than the claim that all cancer has been permanently eliminated.⁠1

The next meaningful advance would be documented, durable outcomes in more patients, accompanied by enough treatment and safety information to judge what NeoOncovac itself adds. For this man, the immediate consequence is simpler: encouraging examinations, a completed course and continued surveillance. The good news is worth reporting. The uncertainty is part of the news, too.